Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2019 2
2020 6
2021 2
2022 4
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
Tumour-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma.
Mizuhara K, Shimura Y, Tsukamoto T, Kanai A, Kuwahara-Ota S, Yamaguchi J, Muramatsu A, Okamoto H, Taminishi-Katsuragawa Y, Kawaji-Kanayama Y, Isa R, Mizutani S, Inaba T, Kuroda J. Mizuhara K, et al. Among authors: isa r. Br J Haematol. 2023 Nov;203(3):426-438. doi: 10.1111/bjh.19049. Epub 2023 Aug 16. Br J Haematol. 2023. PMID: 37584109
Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas.
Katsuragawa-Taminishi Y, Mizutani S, Kawaji-Kanayama Y, Onishi A, Okamoto H, Isa R, Mizuhara K, Muramatsu A, Fujino T, Tsukamoto T, Shimura Y, Taniwaki M, Miyagawa-Hayashino A, Konishi E, Kuroda J. Katsuragawa-Taminishi Y, et al. Among authors: isa r. Cancer Sci. 2023 Dec;114(12):4691-4705. doi: 10.1111/cas.15995. Epub 2023 Oct 15. Cancer Sci. 2023. PMID: 37840379 Free PMC article.
Toward further simplification of elotuzumab therapy by subcutaneous administration.
Shimura Y, Tsukamoto T, Yamaguchi J, Kuwahara-Ota S, Isa R, Nishiyama D, Kobayashi T, Horiike S, Suzuki A, Kuroda J. Shimura Y, et al. Among authors: isa r. Int J Hematol. 2020 Sep;112(3):427-428. doi: 10.1007/s12185-020-02942-6. Epub 2020 Jul 13. Int J Hematol. 2020. PMID: 32656639 No abstract available.
The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.
Isa R, Horinaka M, Tsukamoto T, Mizuhara K, Fujibayashi Y, Taminishi-Katsuragawa Y, Okamoto H, Yasuda S, Kawaji-Kanayama Y, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Sakai T, Kuroda J. Isa R, et al. Int J Mol Sci. 2022 Mar 8;23(6):2919. doi: 10.3390/ijms23062919. Int J Mol Sci. 2022. PMID: 35328342 Free PMC article.
EWSR1 overexpression is a pro-oncogenic event in multiple myeloma.
Nishiyama D, Chinen Y, Isa R, Fujibayashi Y, Kuwahara-Ota S, Yamaguchi J, Takimoto-Shimomura T, Matsumura-Kimoto Y, Tsukamoto T, Shimura Y, Kobayashi T, Horiike S, Taniwaki M, Handa H, Kuroda J. Nishiyama D, et al. Among authors: isa r. Int J Hematol. 2021 Mar;113(3):381-394. doi: 10.1007/s12185-020-03027-0. Epub 2020 Oct 23. Int J Hematol. 2021. PMID: 33095415
Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.
Yamaguchi J, Fujino T, Isa R, Nishiyama D, Kuwahara-Ota S, Kawaji Y, Tsukamoto T, Chinen Y, Shimura Y, Kobayashi T, Horiike S, Kohno K, Nakamura S, Kuroda J. Yamaguchi J, et al. Among authors: isa r. Haematologica. 2019 Aug;104(8):e376-e379. doi: 10.3324/haematol.2019.217141. Epub 2019 Apr 11. Haematologica. 2019. PMID: 30975907 Free PMC article. No abstract available.
Lenalidomide and pomalidomide potently interfere with induction of myeloid-derived suppressor cells in multiple myeloma.
Kuwahara-Ota S, Shimura Y, Steinebach C, Isa R, Yamaguchi J, Nishiyama D, Fujibayashi Y, Takimoto-Shimomura T, Mizuno Y, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Kobayashi T, Horiike S, Taniwaki M, Gütschow M, Kuroda J. Kuwahara-Ota S, et al. Among authors: isa r. Br J Haematol. 2020 Dec;191(5):784-795. doi: 10.1111/bjh.16881. Epub 2020 Jun 19. Br J Haematol. 2020. PMID: 32558939 Free article.
miR-17-92 cluster-BTG2 axis regulates B-cell receptor signaling in mantle cell lymphoma.
Kawaji-Kanayama Y, Tsukamoto T, Nakano M, Tokuda Y, Nagata H, Mizuhara K, Katsuragawa-Taminishi Y, Isa R, Fujino T, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Tashiro K, Kuroda J. Kawaji-Kanayama Y, et al. Among authors: isa r. Cancer Sci. 2024 Feb;115(2):452-464. doi: 10.1111/cas.16027. Epub 2023 Dec 5. Cancer Sci. 2024. PMID: 38050664 Free PMC article.
Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study.
Kawaji-Kanayama Y, Muramatsu A, Sasaki N, Shimura K, Kiyota M, Fuchida S, Isa R, Fujino T, Matsumura-Kimoto Y, Tsukamoto T, Chinen Y, Mizutani S, Nakao M, Kaneko H, Kawata E, Hirakawa K, Takahashi R, Shimazaki C, Uchiyama H, Uoshima N, Shimura Y, Kobayashi T, Taniwaki M, Kuroda J; Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Kawaji-Kanayama Y, et al. Among authors: isa r. Int J Hematol. 2022 Mar;115(3):350-362. doi: 10.1007/s12185-021-03262-z. Epub 2022 Jan 24. Int J Hematol. 2022. PMID: 35072907
Prognostic model for relapsed/refractory transplant-ineligible diffuse large B-cell lymphoma utilizing the lymphocyte-to-monocyte ratio.
Ide D, Fujino T, Kobayashi T, Egashira A, Miyashita A, Mizuhara K, Isa R, Tsukamoto T, Mizutani S, Uchiyama H, Kaneko H, Uoshima N, Kawata E, Taniwaki M, Shimura Y, Kuroda J. Ide D, et al. Among authors: isa r. Int J Hematol. 2024 Mar 16. doi: 10.1007/s12185-024-03750-y. Online ahead of print. Int J Hematol. 2024. PMID: 38492199
19 results